Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry-Reference-Cited by-同舟云学术

Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry

Published:2019-03-15 Issue:8 Volume:49 Page:1052-1059
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Berg Thomas¹^ORCID,Naumann Uwe²,Stoehr Albrecht³,Sick Christoph⁴,John Christine⁵,Teuber Gerlinde⁶,Schiffelholz Willibold⁷,Mauss Stefan⁸,Lohmann Kristina⁹,König Bettina⁹,Pangerl Andreas⁹,Niederau Claus¹⁰

Affiliation:

1. Section of Hepatology; University Hospital Leipzig; Leipzig Germany

2. UBN/Practice; Berlin Germany

3. IFI Studien und Projekte GmbH; Hamburg Germany

4. Praxisonkologie Bremen; Bremen Germany

5. Practice Dr. med. C. John; Berlin Germany

6. Practice PD Dr. med. G. Teuber; Frankfurt Germany

7. Gastroenterologische Schwerpunktpraxis; Augsburg Germany

8. Center for HIV and Hepatogastroenterology; Düsseldorf Germany

9. AbbVie Germany GmbH & Co. KG; Wiesbaden Germany

10. Katholisches Klinikum Oberhausen, St. Josef-Hospital, Klinik für Innere Medizin, Akademisches Lehrkrankenhaus der Universität Duisburg-Essen; Oberhausen Germany

Funder

Deutsches Zentrum für Infektionsforschung

AbbVie Deutschland

Bristol-Myers Squibb

Gilead Sciences

Janssen-Cilag GmbH

MSD Sharp & Dohme GmbH

Roche Pharma AG

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15222/fullpdf

Reference16 articles.

1. Current therapy for chronic hepatitis C: the role of direct-acting antivirals;Li;Antiviral Res,2017

2. Gilead Sciences, Inc EPCLUSA (sofosbuvir/velpatasvir) Summary of Product Characteristics https://www.ema.europa.eu/documents/product-information/epclusa-epar-product-information_en.pdf

3. Gilead Sciences, Inc VOSEVI (sofosbuvir/velpatasvir/voxilaprevir) Summary of Product Characteristics https://www.ema.europa.eu/documents/product-information/vosevi-epar-product-information_en.pdf

4. AbbVie Inc MAVIRET (glecaprevir/pibrentasvir) Summary of Product Characteristics https://www.ema.europa.eu/documents/product-information/maviret-epar-product-information_en.pdf

5. AASLD-IDSA HCV guidance: recommendations for testing, managing, and treating hepatitis C http://www.hcvguidelines.org

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review;Expert Opinion on Pharmacotherapy;2024-08-12

2. Real-life experience of chronic hepatitis C treatment in Switzerland: a retrospective analysis;Swiss Medical Weekly;2024-06-24

3. Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks;2024-04-10

4. Personalized care approaches to hepatitis C therapy: recent advances and future directions;Expert Review of Anti-infective Therapy;2024-03-11

5. Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal;Acta Médica Portuguesa;2024-02-07